Herpangina

Herpangina is a viral oropharyngeal syndrome defined by the presence of painful vesicular and ulcerative lesions localized to the posterior oropharynx, particularly the tonsillar pillars, soft palate, and uvula. It is most commonly associated with coxsackievirus A (particularly serotype A2, A4, A5, A6, A9, A10, and A16), although coxsackievirus B and certain echoviruses have been implicated. The condition was first described in 1920 and is distinct from herpetic gingivostomatitis due to its posterior lesion distribution. Etiologically, it is classified as a non-bacterial, enteroviral infection with no established vaccine or targeted antiviral agent.

The illness typically begins abruptly with fever, sore throat, headache, anorexia, and neck pain. Within 24–48 hours of symptom onset, small (1–2 mm), grayish, erythematous macules develop, progressing rapidly to vesicles and then shallow ulcers (rarely >5 mm) that persist for 1–7 days. Lesions are characteristically located in the posterior oropharynx—especially the tonsillar pillars—but may involve the soft palate, uvula, or tongue. Most patients experience mild to moderate systemic symptoms; severe complications such as dehydration or secondary bacterial infection are uncommon. In rare instances, high fever or persistent discomfort may necessitate symptomatic intervention.

Herpangina is endemic in many regions, with seasonal peaks in late spring and summer, consistent with increased human-to-human transmission under warm, humid conditions. It is most frequently observed in children aged 1–10 years, though case reports include adolescents and adults. No formal global surveillance data are provided in the source material; however, the disease is recognized in multiple national health systems, including Japan’s weekly sentinel surveillance system, where it is monitored as part of enteroviral syndromes. The reservoir remains human, with asymptomatic shedding contributing to community spread, particularly in settings such as daycare centers and schools.

Transmission occurs primarily through the fecal-oral route—often via contaminated hands, food, or water—and secondarily through respiratory droplets from coughing or sneezing. The virus is shed in saliva, stool, and nasopharyngeal secretions, with infectiousness peaking during the early phase of illness. Environmental persistence has not been quantified in the source material; therefore, the duration of viability on surfaces remains uncharacterized. Close personal contact and shared utensils or toys are considered potential exposure pathways.

Children aged 1–10 years constitute the primary at-risk group, with occasional cases reported in adolescents and adults. Immunocompromised individuals may experience prolonged or atypical presentations, though this is not explicitly documented in the source. No specific occupational, geographic, or behavioral risk factors are delineated beyond general susceptibility to enteroviral infections. The absence of ICD-10/ICD-11 codes in the source precludes standardized coding for epidemiological tracking.

Preventive measures focus on standard hygiene practices: frequent handwashing with soap and water, especially after defecation and before eating; disinfection of high-touch surfaces; and avoidance of sharing food, drinks, or utensils among affected individuals. There is no licensed vaccine for herpangina, and no evidence-based public-health interventions beyond general infection control are specified in the source. In outbreak settings, isolation of symptomatic individuals and enhanced environmental cleaning may reduce transmission risk.

In surveillance contexts, herpangina should be identified by the combination of acute fever, posterior oropharyngeal vesiculoulcerative lesions, and absence of anterior oral involvement—distinguishing it from herpetic gingivostomatitis. As a non-specific clinical syndrome, it is often reported under broader enteroviral or febrile illness categories unless laboratory confirmation is pursued. Given its self-limiting nature and lack of mandatory reporting in most jurisdictions, surveillance relies heavily on passive case detection and clinical suspicion, particularly during peak seasons. Source-backed detail on incidence rates, geographic variation, or long-term sequelae is not available.

1. 1 Wikidata. herpangina.
2. 2 Wikipedia. Herpangina - Wikipedia.

ICD-10

ICD-11

Total cases

1.2M

Peak month

2023-07

Coverage

1 reporting countries · 2012-09-15 → 2026-05-02